News Media & Publications

DR. RAJEENTHERAN SUNTHERALINGAM
MBBS, FRCS (Edin), FRCS (Glasgow), FRCS UROLOGY (Glasgow),
MBU Urology (Mal), AM (Mal)
Advanced Urological training (Bristol Urological Institute, U.K),
Certificate in Urodynamics (Bristol), Urology Board Certificate (Mal)

This section is on newly published findings and treatment in the field of Urology, and is meant to clarify any new journal publications and news media releases.

These new publications are not necessarily standard treatment or findings, and need more rigorous studies to confirm their efficacy.

Dr Rajeentheran will provide critical comments on such new publications and news media releases in this page so to clarify its current status, whether it is still investigative or is an established finding and treatment in Urology, and subsequently clarify any misconceptions on such news media releases and publications.

First Drug for Von Hippel-Lindau-Associated Tumors Approved

— Objective response or stable disease in 100% of renal cell carcinomas The FDA has [...]

16
Aug
FDA Grants Accelerated Approval to Sacituzumab Govitecan for Metastatic Urothelial Cancer

The FDA has granted accelerated approval to sacituzumab govitecan (Trodelvy) to treat patients with locally [...]

19
Apr
Erector spinae plane block for severe renal colic pain

This pilot clinical feasibility study was recently published in the International Journal of Clinical Practices [...]

05
Apr
Tivozanib has now been added to the NCCN Guidelines for Renal Cell Carcinoma

Tivozanib (Fotivda) has been added to the National Comprehensive Cancer Network (NCCN) guidelines for use [...]

03
Apr
How To Prevent Kidney Stones

Increasing fluid intake and making dietary lifestyle changes can prevent future stones or at least [...]

03
Apr
FDA Approves Tivozanib for Relapsed/Refractory Advanced Renal Cell Carcinoma

The FDA approved the angiogenesis inhibitor tivozanib (Fotivda) for relapsed/refractory advanced renal cell carcinoma (RCC). [...]

03
Apr
FDA Approves Mirabegron For Children

The U.S. Food and Drug Administration on 25th March 2021 approved a new indication for [...]

03
Apr
FDA Approves Gallium PSMA-Targeted PET Imaging for Prostate Cancer

The U.S. Food and Drug Administration has approved Gallium 68 PSMA-11 (Ga 68 PSMA-11) for [...]

01
Dec
Nadofaragene firadenovec published data show strong efficacy in BCG-unresponsive NMIBC

Nadofaragene firadenovec induced complete responses (CRs) in over half of patients with high-grade, BCG-unresponsive non-muscle [...]

01
Dec
Mitomycin Gel for Low-Grade Upper Tract Urothelial Carcinoma

Tumor-ablative chemotherapy for low-grade upper tract urothelial carcinoma (UTUC) using a mitomycin gel formulation approved [...]

24
Nov
FDA approves lumasiran as first drug for primary hyperoxaluria type 1

Supported by data from the phase 3 ILLUMINATE-A and ILLUMINATE-B studies, the FDA has approved [...]

24
Nov
FDA approves less-frequent dose of durvalumab

Durvalumab is now approved for a dosing schedule of 1500 mg every 4 weeks. Previously [...]

23
Nov
Vibegron update shared as FDA weighs approval in OAB

Vibegron is a selective beta 3 adrenergic receptor (β3AR) agonist. Just like Mirabegron, another drug [...]

23
Nov
FDA Approves First Treatment for Ebola Virus

Comments: This is not a Urology Update. The U.S. Food and Drug Administration approved Inmazeb [...]

15
Oct
Disitamab Vedotin granted FDA breakthrough therapy designation in bladder cancer

Comments: The U.S. FDA has granted Disitamab Vedotin (RC48) a breakthrough therapy designation for the [...]

01
Oct
FDA approves pembrolizumab for BCG-unresponsive, high-risk non-muscle invasive bladder cancer.

Comments – another drug option for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, [...]

24
Sep
PARP Inhibitor Prolongs Overall Survival in mCRPC

Comments: Olaparib increases overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) who [...]

22
Sep
Darolutamide survival benefit in prostate cancer highlighted in NEJM

Comments: Final overall survival data (OS) from the phase 3 ARAMIS trial showed that adding [...]

11
Sep
Nivolumab Plus Cabozantinib Improves OS in CheckMate-9ER Frontline RCC Trial

 “The results from the pivotal CheckMate -9ER trial clearly demonstrate the combination of cabozantinib plus [...]

11
Sep
FDA approves pembrolizumab for BCG-unresponsive, high-risk non-muscle invasive bladder cancer

FDA approves pembrolizumab for BCG-unresponsive, high-risk non-muscle invasive bladder cancer. [...]

07
Sep
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer

Comments: The HERO trial is an international, multicenter study comparing Relugolix (an oral androgen deprivation [...]

07
Sep
Rucaparib pharmacokinetic analyses support use in mCRPC

Comments: The US Food & Drug Administration on May 15, 2020, granted accelerated approval for [...]

07
Sep